Profile for Hong Kong Patent: 1255187

US Patent Family Members and Approved Drugs for Hong Kong Patent: 1255187

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Dec 31, 2036	Acrotech Biopharma	ADQUEY	difamilast

Key insights for pharmaceutical patentability - Hong Kong patent HK1255187

Last updated: May 2, 2026

Hong Kong Drug Patent HK1255187: Scope, Claims, and Patent Landscape

HK1255187 sits in Hong Kong’s published patent record for drug protection, but a complete, claim-level scope analysis and landscape map cannot be produced from the information available in this chat session. Under strict requirements for accuracy and completeness, no substantive claim chart, coverage boundaries, term/validity posture, assignee and family graph, or freedom-to-operate impact can be generated without the underlying patent document text (claims/specification) and the connected family/publication records.

What is HK1255187’s claim scope at the independent claim level?

No claim text or claim set for HK1255187 is provided here, so the scope cannot be analyzed (e.g., drug substance definition, salts/hydrates, polymorphs, dosing regimen, formulation, routes of administration, markers/biomarkers, method-of-treatment limitations, or device/kit exclusions).

What do the dependent claims narrow or add?

No dependent-claim listing is provided, so the narrowing elements cannot be identified (e.g., specific embodiments, concentration ranges, excipients, manufacturing steps, stability parameters, or patient subsets).

Does HK1255187 map to a known international family (PCT/EP/US/CN/JP) and which priority?

No bibliographic data (applicant/assignee, priority date, publication numbers, filing dates, and family member identifiers) is present here, so family linkage and priority chain mapping cannot be performed.

How does HK1255187 interact with generics, biosimilars, or line extensions in Hong Kong?

No regulatory linkage or competitor patent list for Hong Kong is provided in this session, so infringement-risk mapping against likely generic routes, formulation variants, or process patents cannot be established.

What is the patent landscape shape around HK1255187 in Hong Kong (inventor/assignee clusters, expiration, and overlapping families)?

No landscape dataset (citations, CPC/IPC scope, prosecution history, related Hong Kong filings, or near-neighbor families) is provided here, so clustering and overlap analysis cannot be built.

Key Takeaways

• HK1255187’s claim scope cannot be determined without the patent’s claim set and specification text.
• Dependent-claim narrowing, formulation and dosage coverage, and method-of-treatment boundaries cannot be extracted without the document.
• A defensible family graph, priority mapping, and Hong Kong-specific landscape overlap cannot be produced without the bibliographic and prosecution records.

---

FAQs

1. Can you summarize HK1255187’s independent claims without the claim text?
   No.

2. Can you identify whether HK1255187 covers salts, polymorphs, or specific formulations?
   No.

3. Can you determine HK1255187’s priority date and family members without publication data?
   No.

4. Can you assess likely generic infringement risk in Hong Kong without a generics/ANDA/similar comparison and patent list?
   No.

5. Can you compute estimated expiration windows and overlap periods without bibliographic dates and legal status?
   No.

---

References

[1] Hong Kong Intellectual Property Department (HKIPD) patent publication/record for HK1255187 (not provided in this session).